HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BDB001

toll-like receptor 7 and 8 (TLR7/8) agonist

Also Known As:

BDB 001; BDB-001

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- BDB001: 1

Related Diseases

1.	Inflammation (Inflammations) 02/01/2023 - "BDB-001, a recombinant human immunoglobulin G4 (IgG4) that specially binds to C5a, has the potential to inhibit the C5a-triggered cytokine storm in treating COVID-19 patients and other inflammation diseases. "
2.	COVID-19 02/01/2023 - "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults." 02/01/2023 - "BDB-001, a recombinant human immunoglobulin G4 (IgG4) that specially binds to C5a, has the potential to inhibit the C5a-triggered cytokine storm in treating COVID-19 patients and other inflammation diseases. "
3.	Cytokine Release Syndrome 02/01/2023 - "BDB-001, a recombinant human immunoglobulin G4 (IgG4) that specially binds to C5a, has the potential to inhibit the C5a-triggered cytokine storm in treating COVID-19 patients and other inflammation diseases. "

Related Drugs and Biologics

1.	Immunoglobulins (Immunoglobulin)
2.	Immunoglobulin G (IgG)